BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yin C, Zhang T, Li F, Yang F, Putatunda R, Young WB, Khalili K, Hu W, Zhang Y. Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS 2016;30:1163-74. [PMID: 26990633 DOI: 10.1097/QAD.0000000000001079] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Sanches-da-Silva GN, Medeiros LFS, Lima FM. The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy. Int J Genomics 2019;2019:8458263. [PMID: 31531340 DOI: 10.1155/2019/8458263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Moranguinho I, Valente ST. Block-And-Lock: New Horizons for a Cure for HIV-1. Viruses 2020;12:E1443. [PMID: 33334019 DOI: 10.3390/v12121443] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
3 Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Mol Ther Methods Clin Dev 2020;18:532-57. [PMID: 32775490 DOI: 10.1016/j.omtm.2020.06.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
4 Escalona-Noguero C, López-Valls M, Sot B. CRISPR/Cas technology as a promising weapon to combat viral infections. Bioessays 2021;43:e2000315. [PMID: 33569817 DOI: 10.1002/bies.202000315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Henderson LJ, Reoma LB, Kovacs JA, Nath A. Advances toward Curing HIV-1 Infection in Tissue Reservoirs. J Virol 2020;94:e00375-19. [PMID: 31694954 DOI: 10.1128/JVI.00375-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
6 Bradford J, Perrin D. A benchmark of computational CRISPR-Cas9 guide design methods. PLoS Comput Biol 2019;15:e1007274. [PMID: 31465436 DOI: 10.1371/journal.pcbi.1007274] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
7 Roychoudhury P, De Silva Feelixge H, Reeves D, Mayer BT, Stone D, Schiffer JT, Jerome KR. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biol 2018;16:75. [PMID: 29996827 DOI: 10.1186/s12915-018-0544-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
8 Maslennikova A, Mazurov D. Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection. Front Cell Infect Microbiol 2022;12:880030. [DOI: 10.3389/fcimb.2022.880030] [Reference Citation Analysis]
9 Pham HT, Mesplède T. The latest evidence for possible HIV-1 curative strategies. Drugs Context 2018;7:212522. [PMID: 29497452 DOI: 10.7573/dic.212522] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
10 Shim G, Kim D, Park GT, Jin H, Suh SK, Oh YK. Therapeutic gene editing: delivery and regulatory perspectives. Acta Pharmacol Sin 2017;38:738-53. [PMID: 28392568 DOI: 10.1038/aps.2017.2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 13.6] [Reference Citation Analysis]
11 Dampier W, Sullivan NT, Chung CH, Mell JC, Nonnemacher MR, Wigdahl B. Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. Sci Rep 2017;7:14413. [PMID: 29089503 DOI: 10.1038/s41598-017-12612-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
12 White MK, Kaminski R, Young WB, Roehm PC, Khalili K. CRISPR Editing Technology in Biological and Biomedical Investigation. J Cell Biochem 2017;118:3586-94. [PMID: 28460414 DOI: 10.1002/jcb.26099] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
13 Panfil AR, London JA, Green PL, Yoder KE. CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus. Front Microbiol 2018;9:3107. [PMID: 30619186 DOI: 10.3389/fmicb.2018.03107] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
14 Ophinni Y, Miki S, Hayashi Y, Kameoka M. Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape. Viruses 2020;12:E1223. [PMID: 33126728 DOI: 10.3390/v12111223] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kaminski R, Chen Y, Salkind J, Bella R, Young WB, Ferrante P, Karn J, Malcolm T, Hu W, Khalili K. Negative Feedback Regulation of HIV-1 by Gene Editing Strategy. Sci Rep 2016;6:31527. [PMID: 27528385 DOI: 10.1038/srep31527] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
16 Khalili K, White MK, Jacobson JM. Novel AIDS therapies based on gene editing. Cell Mol Life Sci 2017;74:2439-50. [PMID: 28210784 DOI: 10.1007/s00018-017-2479-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
17 Das AT, Binda CS, Berkhout B. Elimination of infectious HIV DNA by CRISPR-Cas9. Curr Opin Virol 2019;38:81-8. [PMID: 31450074 DOI: 10.1016/j.coviro.2019.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
18 Mancuso P, Chen C, Kaminski R, Gordon J, Liao S, Robinson JA, Smith MD, Liu H, Sariyer IK, Sariyer R, Peterson TA, Donadoni M, Williams JB, Siddiqui S, Bunnell BA, Ling B, MacLean AG, Burdo TH, Khalili K. CRISPR based editing of SIV proviral DNA in ART treated non-human primates. Nat Commun 2020;11:6065. [PMID: 33247091 DOI: 10.1038/s41467-020-19821-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
19 Cui J, Techakriengkrai N, Nedumpun T, Suradhat S. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci Rep 2020;10:9617. [PMID: 32541822 DOI: 10.1038/s41598-020-66775-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
20 Sullivan NT, Dampier W, Chung CH, Allen AG, Atkins A, Pirrone V, Homan G, Passic S, Williams J, Zhong W, Kercher K, Desimone M, Li L, C Antell G, Mell JC, Ehrlich GD, Szep Z, Jacobson JM, Nonnemacher MR, Wigdahl B. Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients. Sci Rep 2019;9:17088. [PMID: 31745112 DOI: 10.1038/s41598-019-52353-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
21 Lee C. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules 2019;24:E1349. [PMID: 30959782 DOI: 10.3390/molecules24071349] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
22 Zhao N, Wang G, Das AT, Berkhout B. Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance. Antimicrob Agents Chemother 2017;61:e01486-17. [PMID: 28893790 DOI: 10.1128/AAC.01486-17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
23 Liu Y, Jeeninga RE, Klaver B, Berkhout B, Das AT. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line. Viruses 2021;13:2461. [PMID: 34960730 DOI: 10.3390/v13122461] [Reference Citation Analysis]
24 White MK, Hu W, Khalili K. Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog 2016;12:e1005953. [PMID: 27930735 DOI: 10.1371/journal.ppat.1005953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
25 Binda CS, Klaver B, Berkhout B, Das AT. CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA. Viruses 2020;12:E330. [PMID: 32197474 DOI: 10.3390/v12030330] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
26 Yin C, Zhang T, Qu X, Zhang Y, Putatunda R, Xiao X, Li F, Xiao W, Zhao H, Dai S, Qin X, Mo X, Young WB, Khalili K, Hu W. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther. 2017;25:1168-1186. [PMID: 28366764 DOI: 10.1016/j.ymthe.2017.03.012] [Cited by in Crossref: 153] [Cited by in F6Publishing: 143] [Article Influence: 30.6] [Reference Citation Analysis]
27 Dampier W, Sullivan NT, Mell JC, Pirrone V, Ehrlich GD, Chung CH, Allen AG, DeSimone M, Zhong W, Kercher K, Passic S, Williams JW, Szep Z, Khalili K, Jacobson JM, Nonnemacher MR, Wigdahl B. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics. AIDS Res Hum Retroviruses 2018;34:950-60. [PMID: 29968495 DOI: 10.1089/AID.2017.0274] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
28 Nguyen H, Wilson H, Jayakumar S, Kulkarni V, Kulkarni S. Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System. Viruses 2021;13:1850. [PMID: 34578431 DOI: 10.3390/v13091850] [Reference Citation Analysis]
29 Lebbink RJ, de Jong DC, Wolters F, Kruse EM, van Ham PM, Wiertz EJ, Nijhuis M. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep 2017;7:41968. [PMID: 28176813 DOI: 10.1038/srep41968] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 14.8] [Reference Citation Analysis]
30 Yoder KE. A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness. Acta Virol 2019;63:129-38. [PMID: 31230441 DOI: 10.4149/av_2019_201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Bella R, Kaminski R, Mancuso P, Young WB, Chen C, Sariyer R, Fischer T, Amini S, Ferrante P, Jacobson JM, Kashanchi F, Khalili K. Removal of HIV DNA by CRISPR from Patient Blood Engrafts in Humanized Mice. Mol Ther Nucleic Acids 2018;12:275-82. [PMID: 30195766 DOI: 10.1016/j.omtn.2018.05.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
32 Dong Z, Dong F, Yu X, Huang L, Jiang Y, Hu Z, Chen P, Lu C, Pan M. Excision of Nucleopolyhedrovirus Form Transgenic Silkworm Using the CRISPR/Cas9 System. Front Microbiol 2018;9:209. [PMID: 29503634 DOI: 10.3389/fmicb.2018.00209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
33 Helfer-Hungerbuehler AK, Shah J, Meili T, Boenzli E, Li P, Hofmann-Lehmann R. Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro. Viruses 2021;13:1636. [PMID: 34452500 DOI: 10.3390/v13081636] [Reference Citation Analysis]
34 Jacobson JM, Khalili K. Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed. AIDS Rev 2018;20:220-5. [PMID: 30548022 DOI: 10.24875/AIDSRev.18000027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Chung CH, Allen AG, Atkins AJ, Sullivan NT, Homan G, Costello R, Madrid R, Nonnemacher MR, Dampier W, Wigdahl B. Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites. Mol Ther Nucleic Acids 2020;21:965-82. [PMID: 32818921 DOI: 10.1016/j.omtn.2020.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhang Y, Arango G, Li F, Xiao X, Putatunda R, Yu J, Yang XF, Wang H, Watson LT, Zhang L, Hu W. Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling. BMC Med Genomics 2018;11:78. [PMID: 30200981 DOI: 10.1186/s12920-018-0394-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Chung CH, Allen AG, Atkins A, Link RW, Nonnemacher MR, Dampier W, Wigdahl B. Computational Design of gRNAs Targeting Genetic Variants Across HIV-1 Subtypes for CRISPR-Mediated Antiviral Therapy. Front Cell Infect Microbiol 2021;11:593077. [PMID: 33768011 DOI: 10.3389/fcimb.2021.593077] [Reference Citation Analysis]
38 Liang C, Wainberg MA, Das AT, Berkhout B. CRISPR/Cas9: a double-edged sword when used to combat HIV infection. Retrovirology 2016;13:37. [PMID: 27230886 DOI: 10.1186/s12977-016-0270-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
39 Atkins A, Chung CH, Allen AG, Dampier W, Gurrola TE, Sariyer IK, Nonnemacher MR, Wigdahl B. Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR/Cas9 in HIV-1 Therapy. Front Genome Ed 2021;3:673022. [PMID: 34713260 DOI: 10.3389/fgeed.2021.673022] [Reference Citation Analysis]